Dendreon’s Provenge, which targets prostate cancer, catapulted that company’s stock to record highs recently. Prima Biomed’s CVac works similarly, but it has the potential to target multiple forms of cancer, giving the company an intriguing future.
Continue reading Inside Wall Street: Is This Tiny Aussie Biotech the Next Dendreon?
Inside Wall Street: Is This Tiny Aussie Biotech the Next Dendreon? originally appeared on DailyFinance on Wed, 06 Oct 2010 07:30:00.
Filed Under: Company News, Columns, Investing, Health Care